In our first article, we recognised the value of Veradigm’s data. The era of artificial intelligence has clearly began and in time it will be abundantly clear that AI frameworks will be commoditised and high quality data sets will create high barriers to entry. Poor quality data, regardless of the quality of the AI developed, will provide poor quality results. As the interim CEO, Shib-Yin Ho pointed out in the recent JP Morgan Healthcare Conference:
“We have scalable, high-quality data assets. We sit at the intersection of providers, payers and life science companies. We have deep health care ecosystem expertise. And now with AI, we have the ability to jump forward with our product offerings by harvesting and monetizing the data and analytics of our existing business.”
The opportunity is two fold,
the adoption of AI as a long term tailwind and,
a deeply undervalued business due in large part to noise and confusion surrounding prior financial statements which looks to be addressed with new competent management.
“The absence of a delayed filings and audit sobering, in my judgment has skewered attention from those healthy fundamentals and understandably so, you haven't seen numbers for quite some time.” - Leland Westerfield, interim CFO.
Contents:
Management Changes
Restated financials
Opportunity
Valuation
Listen to this episode with a 7-day free trial
Subscribe to The Bottom-Up Bulletin to listen to this post and get 7 days of free access to the full post archives.
